FRLN Articles, Freeline Therapeutics Holdings plc - From 04/24/24

Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1...

LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announ...

LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announ...

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...

London-listed Syncona Ltd has agreed to acquire Freeline Therapeutics Holdings plc (NASDAQ: FRLN) in an all-cash transaction fo...

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona's ini...

Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 ban...

LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will present new clinical da...

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) reported initial data from the ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associ...